₹366.65
▼ -4.34 -1.17%
As of 13 Nov 2026 · delayed
BSE Listed
Titan Biotech Ltd. (524717)
Volume: 36,711Avg Vol 1W: 60,095Avg Vol 1M: 42,64452W Range:₹137.12₹555.65
Key Ratios
Checked 2h agoMarket Cap₹1,894 Cr
Current Price₹366.65
Previous Close₹370.99
High / Low (52w)₹555.65 / ₹137.12
Volume36,711
Avg Vol (1W)60,095
Avg Vol (1M)42,644
Stock P/E48.95
Book Value₹39.27
Dividend Yield11%
ROE19.06%
ROA14.34%
Revenue (TTM)—
Revenue Growth—
Profit Margin16.05%
Total Debt—
Shares Outstanding5 Cr
Face Value—
EPS (TTM)₹7.49
P/B9.34
Debt / Equity0.03
50 DMA₹386.57
200 DMA₹385.43
Day change-1.17%
Price Chart
₹366.65▲ 84.97% · 1Y
2025-11-142026-11-13
20-day avg volume: 45K shares
Pros
- Healthy return on equity of 19.1%.
- Pays a dividend yield of 11.0%.
- Company is almost debt-free.
- Revenue grew 29% YoY.
- Net profit is growing year over year.
Quarterly Results
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹38 Cr | ₹35 Cr | ₹47 Cr | ₹54 Cr | ₹57 Cr | ₹49 Cr | ₹59 Cr | ₹76 Cr |
| EBITDA | ₹5 Cr | ₹5 Cr | ₹8 Cr | ₹9 Cr | ₹11 Cr | ₹11 Cr | ₹13 Cr | ₹15 Cr |
| Net Profit | ₹4 Cr | ₹4 Cr | ₹7 Cr | ₹8 Cr | ₹9 Cr | ₹7 Cr | ₹11 Cr | ₹13 Cr |
| EPS | — | — | — | — | — | — | — | — |
Profit & Loss (Annual)
| Metric | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Mar 2026 | Jun 2026 | Sept 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹160 Cr | ₹47 Cr | ₹54 Cr | ₹57 Cr | ₹49 Cr | ₹212 Cr | ₹59 Cr | ₹76 Cr |
| EBITDA | ₹25 Cr | ₹8 Cr | ₹9 Cr | ₹11 Cr | ₹11 Cr | ₹39 Cr | ₹13 Cr | ₹15 Cr |
| Net Profit | ₹22 Cr | ₹6 Cr | ₹7 Cr | ₹8 Cr | ₹7 Cr | ₹30 Cr | ₹9 Cr | ₹11 Cr |
| EPS | 26.06 | — | — | — | — | 7.23 | — | — |
Balance Sheet
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | ₹65 Cr | ₹76 Cr | ₹101 Cr | ₹108 Cr | ₹135 Cr | ₹157 Cr | ₹175 Cr | ₹214 Cr |
| Total Liabilities | ₹31 Cr | ₹34 Cr | ₹28 Cr | ₹22 Cr | ₹25 Cr | ₹24 Cr | ₹21 Cr | ₹32 Cr |
| Equity | ₹34 Cr | ₹42 Cr | ₹72 Cr | ₹86 Cr | ₹110 Cr | ₹133 Cr | ₹153 Cr | ₹182 Cr |
| Total Debt | — | — | — | — | — | — | — | — |
Cash Flow
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating | ₹7 Cr | ₹8 Cr | ₹30 Cr | ₹29 Cr | ₹29 Cr | ₹29 Cr | ₹26 Cr | ₹39 Cr |
| Investing | ₹-4 Cr | ₹-2 Cr | ₹-5 Cr | ₹-16 Cr | ₹-21 Cr | ₹-20 Cr | ₹-10 Cr | ₹-33 Cr |
| Financing | ₹0 Cr | ₹-4 Cr | ₹-11 Cr | ₹-4 Cr | ₹-2 Cr | ₹-3 Cr | ₹-8 Cr | ₹-2 Cr |
| Free Cash Flow | ₹7 Cr | ₹8 Cr | ₹30 Cr | ₹29 Cr | ₹29 Cr | ₹29 Cr | ₹26 Cr | ₹39 Cr |
Shareholding
Promoter 55.78% Institutions 0.01% Public 44.21%
Efficiency & Working Capital
ROCE23.8%
Interest Coverage43
Dividend Payout—
Debtor Days40 d
Inventory Days99 d
Payable Days15 d
Cash Conversion Cycle124 d
Working Capital Days139 d
Shareholding Details
As of 2026-09-30
Promoter55.8%
FII0%
DII0%
Institutions0%
Public44.2%
Promoter Pledge0%
No. of Shareholders19,049
Shareholding Pattern
Quarterly — figures in %. Latest 12 quarters.
| Period | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 55.9% | 55.9% | 55.9% | 55.9% | 55.9% | 55.9% | 55.9% | 55.8% | 55.8% | 55.8% | 55.8% | 55.8% |
| FIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| DIIs | 0% | 0.2% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 44.1% | 43.9% | 44.1% | 44.1% | 44.1% | 44.1% | 44.1% | 44.2% | 44.2% | 44.2% | 44.2% | 44.2% |
| Promoter Pledge | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| No. of Shareholders | 15,756 | 15,876 | 15,850 | 15,700 | 16,038 | 16,370 | 16,328 | 16,040 | 16,367 | 17,457 | 18,671 | 19,049 |
Returns History (ROE / ROCE / ROA)
| Period | ROE | ROCE | ROA | P/E |
|---|---|---|---|---|
| 202603 | — | — | — | — |
Major Shareholders (>1%)
| Name | Category | Stake | Shares |
|---|---|---|---|
| Titan Securities Limited | Shareholding of Promoter and Promoter Group | 33.6% | 1.39 Cr |
| Tanita Leasing & Finance Limited | Shareholding of Promoter and Promoter Group | 9.5% | 39,22,275 |
| Investor Education And Protection Fund Authority Ministry Of Corporate Affairs | Public Shareholding | 9.4% | 38,73,525 |
| Connoisseur Management Services Private Limit | Shareholding of Promoter and Promoter Group | 6.8% | 28,00,000 |
| Manish Goel | Public Shareholding | 2.8% | 11,61,442 |
| Titan Biotech Limited Unclaimed Suspense Demat Account | Public Shareholding | 2.3% | 9,52,005 |
| Suresh Chand Singla | Shareholding of Promoter and Promoter Group | 1.3% | 5,28,355 |
| Manju Singla | Shareholding of Promoter and Promoter Group | 0.9% | 3,56,050 |
| Madhu Gupta | Shareholding of Promoter and Promoter Group | 0.8% | 3,32,550 |
| Raja Singla | Shareholding of Promoter and Promoter Group | 0.7% | 3,05,500 |
| Supriya Singla | Shareholding of Promoter and Promoter Group | 0.7% | 2,72,465 |
| Udit Singla | Shareholding of Promoter and Promoter Group | 0.6% | 2,50,000 |
| Shivom Singla | Shareholding of Promoter and Promoter Group | 0.4% | 1,77,000 |
| Naresh Kumar Singla | Shareholding of Promoter and Promoter Group | 0.4% | 1,72,550 |
| Naresh Kumar Singla Huf | Shareholding of Promoter and Promoter Group | 0.1% | 50,000 |
| Ravinder Gupta Huf | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Ravinder Gupta | Shareholding of Promoter and Promoter Group | 0% | 0 |
Board of Directors
| Name | Designation | Year |
|---|---|---|
| Rohit Jain | Chairman & Independent Directo | 2025 |
| Naresh Kumar Singla | ED / MD / Promoter | 2025 |
| Suresh Chand Singla | ED / MD / Promoter | 2025 |
| Manju Singla | Non-Exec & Non-Independent Dir | 2025 |
| Supriya Singla | Non-Exec & Non-Independent Dir | 2025 |
| Dhairya Madan | Independent Non Exe. Director | 2025 |
| Brijesh Kumar Singh | Independent Non Exe. Director | 2025 |
| Abhishek Agarwal | Independent Non Exe. Director | 2025 |
| Raja Singla | WTD & Executive Director | 2025 |
| Udit Singla | E D & Wholetime Director | 2025 |
| Shivom Singla | E D & Wholetime Director | 2025 |
| Debendra Kumar Sabat | Independent Non Exe. Director | 2025 |
| CHARANJIT SINGH | Company Sec. & Compli. Officer | 2025 |
Segments — Geography
| Region | Revenue | Share |
|---|---|---|
| Domestic | ₹126 Cr | 61% |
| Overseas | ₹80 Cr | 39% |
Capital Structure (₹ Cr)
| Year | Face Value | Authorised | Issued | Paid-up |
|---|---|---|---|---|
| 2026 | ₹2 | 10 | 8 | 8 |
Corporate Actions
| Type | Date | Value | Remark |
|---|---|---|---|
| bonus | 2026-10-23 | 1:4 | 1:4 Bonus Issue of Equity Shares |
| forthcoming | 2026-10-23 | Bonus | — |
| forthcoming | 2026-09-22 | Dividend | — |
| dividend | 2026-09-22 | ₹0.5 (25%) | Final |
| forthcoming | 2026-08-13 | Board Meetings | — |
| split | 2026-02-20 | 1:5 | face value change from 10 to 2 |
| dividend | 2025-09-19 | ₹2 (20%) | Final |
Related-Party Transactions (₹ Cr)
| Year | Subsidiaries | Associates | JV | KMP | Others | Total |
|---|---|---|---|---|---|---|
| 2026 | 0 | 16 | 0 | 7 | 40 | 63 |
| 2026 | 0 | 9 | 0 | 0 | 0 | 9 |
| 2026 | 0 | 3 | 0 | 7 | 39 | 49 |
Insider / Designated-Person Trades
1 recent disclosure(s)
RAVINDER GUPTA HUFDisposal · 21
Company Information
🌐 www.titanbiotechltd.com ↗
📍 A-902 A RIICO Industrial Area, Phase III Alwar District, Bhiwadi, Rajasthan, 301019
Technical AnalysisPremium
Technical analysis (Premium)
Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.
More stocks
Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search